This Wilmington biotech startup develops AI-based software for cell and gene therapy. It was founded in 2021 by Spark Therapeutics alum Irene Rombel and MIT professor Richard Braatz. Its mAI Platform claims to be the first scalable AI-driven platform for CGT process development and manufacturing.